Thomas D Pollard

Mr. Thomas D Pollard

School of Pharmacy, University College London

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
Atheer AwadAtheer Awad
Atheer Awad
STSarah J. Trenfield
Sarah J. Trenfield
TPThomas D Pollard
Thomas D Pollard
JOJun Jie Ong
Jun Jie Ong
MEMoe Elbadawi
Moe Elbadawi
ABAbdul W Basit
Abdul W Basit

1 September 2021 in Journal of Controlled Release
Verified
Journal Article
Closed access
BCBrais Muñiz Castro
Brais Muñiz Castro
MEMoe Elbadawi
Moe Elbadawi
JOJun Jie Ong
Jun Jie Ong
TPThomas D Pollard
Thomas D Pollard
ZSZhe Song
Zhe Song
AGAlvaro Goyanes
Alvaro Goyanes

16 December 2020 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
MEMoe Elbadawi
Moe Elbadawi
JOJun Jie Ong
Jun Jie Ong
TPThomas D Pollard
Thomas D Pollard
SGSimon Gaisford
Simon Gaisford
ABAbdul W Basit
Abdul W Basit

1 January 2021 in Drug Discovery Today
Verified
Journal Article
Closed access
TPThomas D Pollard
Thomas D Pollard
JOJun Jie Ong
Jun Jie Ong
AGAlvaro Goyanes
Alvaro Goyanes
MOMine Orlu
Mine Orlu
SGSimon Gaisford
Simon Gaisford
ABAbdul W Basit
Abdul W Basit

1 September 2021 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
JOJun Jie Ong
Jun Jie Ong
TPThomas D Pollard
Thomas D Pollard
AGAlvaro Goyanes
Alvaro Goyanes
SGSimon Gaisford
Simon Gaisford
MEMohammed Elbadawi
Mohammed Elbadawi
ABAbdul W Basit
Abdul W Basit

19 February 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TPThomas D Pollard
Thomas D Pollard
MBMargherita Bonetti
Margherita Bonetti
ADAdam Day
Adam Day
Simon GaisfordSimon Gaisford
Simon Gaisford
Mine OrluMine Orlu
Mine Orlu
AGAlvaro Goyanes
Alvaro Goyanes
Inkjet printing (IJP) is an emerging technology for the precision dosing of medicines. We report, for the first time, the printing of the antifungal drug terbinafine hydrochloride directly onto nails for the treatment of onychomycosis. A commercial cosmetic nail printer was modified by removing the ink from the cartridge and replacing it with an in-house prepared drug-loaded ink. The drug-loaded ink was designed so that it was comparable to the commercial ink for key printability properties. Linear drug dosing was shown by changing the lightness of the colour selected for printing (R2 = 0.977) and by printing multiple times (R2 = 0.989). The drug loads were measured for heart (271 µg), world (205 µg) and football (133 µg) shapes. A disc diffusion assay against Trpytophan rubrum showed inhibition of fungal growth with printed-on discs. In vitro testing with human nails showed substantial inhibition with printed-on nails. Hence, this is the first study to demonstrate the ability of a nail printer for drug delivery, thereby confirming its potential for onychomycosis treatment.